Featured Research

from universities, journals, and other organizations

Lowering Resistance To Insulin May Delay Or Prevent Onset Of Type 2 Diabetes

Date:
June 12, 2005
Source:
University of Southern California
Summary:
Type 2 diabetes may be significantly delayed or prevented through medication that takes the load off of the body's delicate insulin-producing cells.

SAN DIEGO (June 11, 2005)-Type 2 diabetes may be significantly delayed or prevented through medication that takes the load off of the body's delicate insulin-producing cells, according to a study released today by researchers at the Keck School of Medicine of the University of Southern California.

They presented their findings at the American Diabetes Association's 65th Scientific Sessions.

The Pioglitazone in Prevention of Diabetes (PIPOD) study tested whether the drug pioglitazone could protect women who had had gestational diabetes-a temporary form of diabetes during pregnancy-from developing type 2 diabetes later, explains study presenter Thomas A. Buchanan, M.D., professor of medicine, obstetrics and gynecology and physiology and biophysics at the Keck School.

Although most women with gestational diabetes do not remain diabetic right after delivery, they do commonly remain resistant to their insulin, and 30 to 50 percent of them develop type 2 diabetes within a few years after pregnancy. Because of that, studying women with gestational diabetes is useful for researchers seeking to understand diabetes and develop ways to prevent it.

In the study, researchers provided pioglitazone for three years to 89 women who had had gestational diabetes and who had already participated in their diabetes prevention study called TRIPOD, which used the drug troglitazone. Troglitazone reduced diabetes risk from 12 percent a year to only 5 percent a year. However, troglitazone was removed from use in 2000 because it caused rare but severe liver damage in those with type 2 diabetes.

For PIPOD, researchers used pioglitazone (also called Actos), which works similarly to troglitazone but is safe for the liver, to see if the diabetes rate would remain low. It did, less than 5 percent each year. Moreover, among those women who remained diabetes-free, beta-cell function did not change while the women were taking pioglitazone. Beta cells produce insulin.

As was true in the TRIPOD study, protection from diabetes in PIPOD was closely associated with reduced stress on the beta cells that results when physicians treat insulin resistance, Buchanan says.

"This study shows that our initial findings for diabetes prevention with troglitazone apply not only to this class of drugs-thiazolidinediones-but to the general mechanisms of reducing stress on beta cells by treating insulin resistance," Buchanan says. "Theoretically, weight loss and some other drugs may be able to do the same thing."

Buchanan explains that the body's cells need sugar, or glucose, for energy. Insulin helps cells grab glucose from the blood. But when cells grow resistant to insulin, beta cells must create more insulin to make up that resistance. Researchers believe that in some people, beta cells eventually buckle under the heavy load and wear out. Their failure leads to type 2 diabetes.

Pioglitazone makes the body's cells more sensitive to insulin, reducing beta cells' workload.

Researchers saw further evidence of the importance of treating insulin resistance to protect beta cells, too.

Under the previous study, TRIPOD, some women with gestational diabetes were given a placebo instead of troglitazone. When pioglitazone was substituted for troglitazone, though, all of the women-even those on placebo-were put on pioglitazone.

This is significant because many women who were on placebo during TRIPOD had seen their beta-cell function worsen; but when they were put on pioglitazone during PIPOD, their blood sugar and insulin levels improved, and most significantly, their beta-cell function stabilized.

Buchanan also reports that women who remained free of diabetes in PIPOD had certain factors in common. Before starting to take pioglitazone, they tended to have lower glucose levels and slightly higher insulin levels and their beta cells seemed to compensate more strongly for insulin resistance. After a year on pioglitazone, these women also had a greater reduction in insulin in the blood-a marker of a reduced load on their beta cells.

"This line of research is leading to a rational approach to diabetes prevention and early treatment," Buchanan says. "Patients at increased risk for type 2 diabetes should exercise and keep their weight as close to normal as possible. They should have regular check-ups to see if their glucose levels are stable, which means they are not progressing toward diabetes, or rising, which means they are progressing.

"If they continue to worsen, despite weight control and exercise, medications such as pioglitazone can be used to slow or stop their progression to diabetes."


Story Source:

The above story is based on materials provided by University of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University of Southern California. "Lowering Resistance To Insulin May Delay Or Prevent Onset Of Type 2 Diabetes." ScienceDaily. ScienceDaily, 12 June 2005. <www.sciencedaily.com/releases/2005/06/050612110652.htm>.
University of Southern California. (2005, June 12). Lowering Resistance To Insulin May Delay Or Prevent Onset Of Type 2 Diabetes. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2005/06/050612110652.htm
University of Southern California. "Lowering Resistance To Insulin May Delay Or Prevent Onset Of Type 2 Diabetes." ScienceDaily. www.sciencedaily.com/releases/2005/06/050612110652.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins